Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
EBMT 2022
It was a pleasure to catch up with the lovely @Santin13Valeria of @UNI_FIRENZE at #ASH25 to hear about the long-term outcomes from the randomized Phase III IMerge trial investigating imetelstat for LR-MDS.🩸
Click here to learn more:
🎥
#MDSsm #CTSM…
Long-term outcomes from the Phase III IMerge trial of imetelstat in LR-MDS
In this interview, Valeria Santini, MD, University of Florence, Florence, Italy, discusses the long-term outcomes from ...
ow.ly
Want to know the top updates in CLL from #ASH25?
🎧Listen to our podcast: https://ow.ly/N2pI50XLuak
Featuring Talha Munir, @DrMDavids, @carsten_niemann, Paolo Ghia, Jennifer Woyach, @chanyooncheah & Barbara Eichhorst.
#CLLsm #Leusm #HemOnc
#ASH25 | Alex Herrera of @cityofhope shares three-year follow-up data from the Phase III S1826 trial, which investigated immunotherapy (nivolumab or brentuximab vedotin) plus AVD for the treatment of newly diagnosed stage III-IV classic #HodgkinLymphoma:
🎥…
In an interview from #ASH25, Sabina Chiaretti of @SapienzaRoma shares the first results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult Ph+ ALL.
Watch now:
👉 👈
#ALLsm…
Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, shares the first results of the Phase III GIMEMA ALL28...
ow.ly
We can't believe it's already been two weeks since #ASH25!🤯🩸
Don't forget to explore the hottest trial updates, clinical breakthroughs, and expert insights from the event with our exclusive video interviews.🎥
Click here: ➡️ https://ow.ly/n0FK50XGXWt
#HemOnc #Hematology #CTSM…
EBMT 2022
It was a pleasure to catch up with the lovely @Santin13Valeria of @UNI_FIRENZE at #ASH25 to hear about the long-term outcomes from the randomized Phase III IMerge trial investigating imetelstat for LR-MDS.🩸
Click here to learn more:
🎥
#MDSsm #CTSM…
Long-term outcomes from the Phase III IMerge trial of imetelstat in LR-MDS
In this interview, Valeria Santini, MD, University of Florence, Florence, Italy, discusses the long-term outcomes from ...
ow.ly
Want to know the top updates in CLL from #ASH25?
🎧Listen to our podcast: https://ow.ly/N2pI50XLuak
Featuring Talha Munir, @DrMDavids, @carsten_niemann, Paolo Ghia, Jennifer Woyach, @chanyooncheah & Barbara Eichhorst.
#CLLsm #Leusm #HemOnc
#ASH25 | Alex Herrera of @cityofhope shares three-year follow-up data from the Phase III S1826 trial, which investigated immunotherapy (nivolumab or brentuximab vedotin) plus AVD for the treatment of newly diagnosed stage III-IV classic #HodgkinLymphoma:
🎥…
In an interview from #ASH25, Sabina Chiaretti of @SapienzaRoma shares the first results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult Ph+ ALL.
Watch now:
👉 👈
#ALLsm…
Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, shares the first results of the Phase III GIMEMA ALL28...
ow.ly
We can't believe it's already been two weeks since #ASH25!🤯🩸
Don't forget to explore the hottest trial updates, clinical breakthroughs, and expert insights from the event with our exclusive video interviews.🎥
Click here: ➡️ https://ow.ly/n0FK50XGXWt
#HemOnc #Hematology #CTSM…
